Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.
about
Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease PathogenesisCX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent MannerRespiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virusRespiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial CulturesA respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis.Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantThe respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodentsAssembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Therapeutic targeting of respiratory syncytial virus G-protein.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection.Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Novel antigens for RSV vaccines.Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in miceUniversal vaccine against respiratory syncytial virus A and B subtypes.Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and DiseaseLive-attenuated respiratory syncytial virus vaccines.Viral shedding and immune responses to respiratory syncytial virus infection in older adults.A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSVStructural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignRespiratory syncytial virus: current progress in vaccine development.Advances in and the potential of vaccines for respiratory syncytial virus.Central nervous system alterations caused by infection with the human respiratory syncytial virus.Recent advances in the development of subunit-based RSV vaccines.Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection.Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.Novel clinical features of recurrent human respiratory syncytial virus infections.Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection.Small hydrophobic protein of respiratory syncytial virus as a novel vaccine antigen.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
P2860
Q26823449-B70E36E4-4DBB-4913-B9AA-C5D51D643BEAQ27303940-2AEE17C8-0385-42B3-BB83-C0CF83DB44A4Q28545124-1BCA1423-9589-4A8A-9BC6-DCFA1E18F4ECQ28551477-F530D62D-A1D9-41C0-A5D4-DD89F08B25F6Q33690612-6C900562-4FA4-4D2B-B369-5474A74EC699Q34004492-2F026E4D-4FFB-4713-B9AB-6EC31E763312Q34120278-1BBE3E2A-834E-465B-B66C-83ADAEE045ECQ34182385-69888087-02A1-4959-A106-722E13D8F86EQ34222406-4214E844-68E9-4FFF-A76A-F1DB463B31EBQ34457791-11694F92-7F31-4E0F-94B4-C7060E87E165Q34603346-5C6C8D82-625E-435B-8C76-504CAEC8917FQ34990420-56273BA7-86E3-47A1-B181-D040448D641DQ35077892-5EF855FE-5E5B-41CB-837C-12047D18590DQ35149594-38199D62-839B-4FD9-9AC7-D546342B193CQ35747504-C3923D4E-CDF1-4D78-8DE4-517C93C5A6EBQ36005114-49347FBA-AEE7-4CDE-8C98-6A093C6C0827Q36005960-B05A0B01-029E-4D0F-9D7C-56405A4A1E4BQ36106575-95B3C041-8DA3-4F81-BFBF-E783C9F50E45Q36338294-44325B91-0E42-42B4-88FA-0C74324ED4B6Q36409517-66C58F22-080B-44F1-927D-59D71E922522Q36692801-1DE6F489-AC03-41A4-A828-7847A9DD1C94Q36723340-F460AAA5-2789-4D96-B452-A15D07A4C8E4Q37252918-03C24206-8836-4D1E-A2FF-55C2B819ED6CQ37536191-01D5BB83-B6EB-4B88-B7D0-44BE0D257CB6Q37635077-A56BE720-8A71-4D70-9E9A-F8254EF25886Q37729137-B5F265EA-E977-41F7-B944-8922F3AB9E60Q38079432-6A4FAB1D-3C71-45EE-8F29-EB65691C3439Q38130514-CC5BFDD5-E8DE-4E44-895B-ABD2F7276163Q38260281-C9D51D87-2CD5-49FB-A2E0-E11C01A68599Q38617302-B05B453A-D89C-4FB9-AB3A-2D9640BF9F60Q38660842-4B2113F7-7285-4CE5-BAD7-B170A4CEB4B6Q38696909-DADBD806-2FDC-4587-85D2-3F8261857AF3Q38905050-D9BD0174-4222-407B-ABC9-A013682FF28CQ39289416-AF2A37A9-067F-42C4-A62B-899F7F31D1BEQ39395437-47258E60-81E4-4CB9-A8E8-DF50DB1A2EA7Q40301211-A52CC29F-4B97-4B52-BF75-9149A62F0DBDQ41841268-1CF4FD13-674F-49A3-8048-907FB6319865Q42575063-2FB11B27-1518-42DA-B614-68627C302BFFQ45342736-C584D52F-B71D-4E1F-944A-1ADC014B656DQ47549703-B07B48ED-B8CF-4697-883F-4C3A0A7AB432
P2860
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Vaccination to induce antibodi ...... and virus replication in mice.
@ast
Vaccination to induce antibodi ...... and virus replication in mice.
@en
Vaccination to induce antibodi ...... and virus replication in mice.
@nl
type
label
Vaccination to induce antibodi ...... and virus replication in mice.
@ast
Vaccination to induce antibodi ...... and virus replication in mice.
@en
Vaccination to induce antibodi ...... and virus replication in mice.
@nl
prefLabel
Vaccination to induce antibodi ...... and virus replication in mice.
@ast
Vaccination to induce antibodi ...... and virus replication in mice.
@en
Vaccination to induce antibodi ...... and virus replication in mice.
@nl
P2093
P2860
P356
P1433
P1476
Vaccination to induce antibodi ...... and virus replication in mice.
@en
P2093
Jennifer L Harcourt
Larry J Anderson
Les P Jones
Lia M Haynes
Wenliang Zhang
Youngjoo Choi
P2860
P304
P356
10.1128/JVI.01755-09
P577
2009-10-28T00:00:00Z